Comparative fall risk of patients treated with novel androgen receptor antagonists in prostate cancer: a systematic review and meta-analysis - PubMed
2 hours ago
- #androgen receptor inhibitors
- #prostate cancer
- #fall risk
- ARPIs (enzalutamide, apalutamide, darolutamide) for prostate cancer significantly increase fall risk overall, with RR 2.00 for all-grade and 2.15 for grade ≥3 falls.
- Fall risk varies by agent: enzalutamide shows highest risk (RR 2.55 vs. placebo), apalutamide moderate risk (RR 1.65), while darolutamide has no significant increase (RR 1.25).
- Findings suggest drug-specific fall risks, not a uniform class effect, and highlight the need for individualized treatment, especially in elderly or frail patients.